Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources and Roche Partner on Trastuzumab Emtansine Commercialization to Expand Breast Cancer ADC Access

Fineline Cube Apr 14, 2026
Company Deals

CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China’s NHL Market

Fineline Cube Apr 14, 2026
Company Deals

Erasca Exercises Option to Secure Global Rights to Pan-RAS Molecular Glue ERAS-0015 from Joyo Pharmatech

Fineline Cube Apr 14, 2026
Company Deals

Zuellig Pharma Acquires Cialis Rights for Hong Kong, Macau, and South Korea from Eli Lilly

Fineline Cube Apr 14, 2026
Company Deals

Olymvax Biopharmaceuticals and Westlake University Launch Universal Influenza Vaccine Collaboration

Fineline Cube Apr 14, 2026
Policy / Regulatory

China’s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program

Fineline Cube Apr 14, 2026
Company Drug

Grand Pharmaceutical’s SIR-Spheres Achieves Phase III Success in Unresectable HCC, Supporting China Expansion

Fineline Cube Apr 14, 2026
Company Drug

Zelgen’s Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial – Dual JAK/ACVR1 Inhibitor Expands Beyond Myelofusion

Fineline Cube Apr 14, 2026
Company

Teva Pharmaceutical Reaches Settlement with DOJ Over Alleged Kickbacks and Price-Fixing

Fineline Cube Oct 14, 2024

Teva Pharmaceutical Industries Ltd (NYSE: TEVA), headquartered in Israel, has entered into a settlement agreement...

Company Drug

CSPC Pharma Initiates Phase III Trial for JMT101 in First-Line EGFR-Positive NSCLC Treatment

Fineline Cube Oct 14, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has initiated...

Company Drug

KangaBio’s KGX101 Receives NMPA Approval for Clinical Trial in China

Fineline Cube Oct 13, 2024

KangaBio, a biopharmaceutical company based in Shanghai, has announced that its investigational new drug (IND)...

Drug

Johnson & Johnson’s KLK2-CD3 Bispecific Antibody JNJ-78278343 Advances in Prostate Cancer Clinical Trials

Fineline Cube Oct 13, 2024

JNJ-78278343, a KLK2-CD3 bispecific antibody, is currently in Phase I clinical trials globally. According to...

Company Drug

Merck KGaA’s Pergoveris Treatment Expands Access to Advanced Reproductive Care in Greater Bay Area

Fineline Cube Oct 12, 2024

Merck KGaA (MRK, NYSE: MRK) , a leading science and technology company based in Germany,...

Company Drug

Junshi Biosciences’ Ongericimab Wins NMPA Nod for Hypercholesterolemia Treatment

Fineline Cube Oct 12, 2024

Junshi Biosciences (HKG: 1877; SHA: 688180), a leading biopharmaceutical company in China, has announced that...

Company

WuXi AppTec Addresses Media Speculation on Potential Sale of WuXi ATU

Fineline Cube Oct 12, 2024

WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359, OTCMKTS: WUXAY), a leading China-based Contract Development...

Company Drug

Juventas Cell Therapy’s CAR-T Therapy Clears for SLE-ITP Study in China

Fineline Cube Oct 12, 2024

The China Center for Drug Evaluation (CDE) has given the green light for a study...

Company Deals

Sanofi Commences Negotiations with CD&R for Potential Sale of Opella Stake

Fineline Cube Oct 12, 2024

Sanofi (EPA: SAN; NASDAQ: SNY) has initiated negotiations with private equity firm CD&R for the...

Policy / Regulatory

SAMR Proposes Guidelines to Curb Commercial Bribery in Pharmaceutical Industry

Fineline Cube Oct 12, 2024

The State Administration for Market Regulation (SAMR) has unveiled the “Guidelines for Compliance of Pharmaceutical...

Company Deals

JD Healthcare and Genrix Bio Join Forces to Revolutionize Patient Care and Pharmacy Services

Fineline Cube Oct 12, 2024

JD Healthcare, a subsidiary of China’s e-commerce juggernaut JD.com (NASDAQ: JD), has formed a strategic...

Policy / Regulatory

Guangdong Province Aims for RMB One Trillion in Biopharma Industry Growth by 2027

Fineline Cube Oct 12, 2024

The People’s Government of Guangdong Province has unveiled an ambitious “Action Plan for Further Promoting...

Company Drug

Immupeutics Medicine Secures NMPA Approval for Personalized Liver Cancer Immunotherapy IPM001

Fineline Cube Oct 12, 2024

Immupeutics Medicine, a pioneer in tumor immunotherapy based in Beijing, has announced that it has...

Company Deals

Eli Lilly & Co. Partners with Insitro to Leverage AI in Metabolic Disease Drug Development

Fineline Cube Oct 12, 2024

Eli Lilly & Co. (NYSE: LLY), a stalwart of the US pharmaceutical industry, has inked...

Company Drug

Pfizer’s Hympavzi Secures FDA Nod, Offering Novel Once-Weekly Treatment for Hemophilia B

Fineline Cube Oct 12, 2024

Pfizer Inc. (NYSE: PFE) has scored a significant win with the US Food and Drug...

Company Deals

Hetero and Gilead Sciences Partner to Expand Access to HIV Treatment in Low-Income Countries

Fineline Cube Oct 12, 2024

Indian pharmaceutical company Hetero has announced a new partnership with US healthcare giant Gilead Sciences...

Company Drug

Huadong Medicine Secures NMPA Approval for Semaglutide Biosimilar, Aims to Capture Weight Loss Market

Fineline Cube Oct 11, 2024

Nanjing-based Huadong Medicine Co., Ltd (SHE: 000963) has received clinical trial approval from China’s National...

Company Drug

Coherent Biopharma’s CBP-1008 Earns FDA Fast Track for Platinum-Resistant Ovarian Cancer

Fineline Cube Oct 11, 2024

Coherent Biopharma Ltd, a specialist in bispecific-ligand drug conjugates (Bi-XDCs) with operations in Suzhou, China,...

Company Drug

Doma Biopharmaceutical Receives Green Light for Clinical Trial of Novel ADC DM001 Targeting Solid Tumors

Fineline Cube Oct 11, 2024

Doma Biopharmaceutical (Suzhou) Co., Ltd, a biotech firm with a presence in China and the...

Company Drug

Harbour BioMed’s Innovative Antibody Porustobart Shows Promise in Early Clinical Trials for Melanoma

Fineline Cube Oct 11, 2024

Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands,...

Posts pagination

1 … 270 271 272 … 650

Recent updates

  • Grand Pharmaceutical’s SIR-Spheres Achieves Phase III Success in Unresectable HCC, Supporting China Expansion
  • China Resources and Roche Partner on Trastuzumab Emtansine Commercialization to Expand Breast Cancer ADC Access
  • Zelgen’s Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial – Dual JAK/ACVR1 Inhibitor Expands Beyond Myelofusion
  • China’s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program
  • CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China’s NHL Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Grand Pharmaceutical’s SIR-Spheres Achieves Phase III Success in Unresectable HCC, Supporting China Expansion

Company Deals

China Resources and Roche Partner on Trastuzumab Emtansine Commercialization to Expand Breast Cancer ADC Access

Company Drug

Zelgen’s Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial – Dual JAK/ACVR1 Inhibitor Expands Beyond Myelofusion

Policy / Regulatory

China’s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.